EU/3/04/207

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in July 2016 at the end of the period of market exclusivity.

On 29 July 2004, orphan designation (EU/3/04/207) was granted by the European Commission to Bayer Healthcare AG, Germany, for sorafenib tosylate for the treatment of renal cell carcinoma.

The sponsorship was transferred to Bayer Shering Pharma AG, Germany, in April 2009. Bayer Shering Pharma AG changed its name to Bayer Pharma AG in October 2011.

Update: sorafenib tosylate for treatment of renal cell carcinoma has been authorised in the EU as Nexavar since 19 July 2006.

Key facts

Active substance
Sorafenib tosylate
Medicine name
Nexavar
Disease / condition
Treatment of renal cell carcinoma
Date of decision
29/07/2004
Outcome
Expired
Orphan decision number
EU/3/04/207

Sponsor's contact details

Bayer Pharma AG
13342 Berlin
Germany
Tel. +49 2143 051348
Fax +49 2143 051603
E-Mail: medical-information@bayerhealtcare.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating